2026-04-13T02:24:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/133672025-10-24T10:43:26Zcom_2072_378070com_2072_378040col_2072_378092

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST Perol, Maurice Li, Wei Pennell, Nathan Liu, Geoffrey Ohe, Yuichiro de Braud, Filippo Guglielmo Maria FELIP, ENRIQUETA Institut Català de la Salut [Pérol M] Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France. [Li W] Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China. [Pennell NA] Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. [Liu G] Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, Canada. [Ohe Y] National Cancer Center Hospital, Tokyo, Japan. [De Braud F] University of Milan, Milan, Italy. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Avaluació de resultats (Assistència sanitària) Pulmons - Càncer - Tractament Proteïnes quinases - Inhibidors - Ús terapèutic DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Taletrectinib; Non-small cell lung cancer Taletrectinib Cáncer de pulmón de células no pequeñas Taletrectinib; Càncer de pulmó de cèl·lules no petites Purpose Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1+ non–small cell lung cancer. Methods TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials. Efficacy outcomes were pooled from TRUST-I and TRUST-II pivotal cohorts. The safety population comprised all patients treated with once-daily oral taletrectinib 600 mg pooled across the taletrectinib clinical program. The primary end point was independent review committee–assessed confirmed objective response rate (cORR). Secondary outcomes included intracranial (IC)-ORR, progression-free survival (PFS), duration of response (DOR), and safety. Results As of June 7, 2024, the efficacy-evaluable population included 273 patients in TRUST-I and TRUST-II. Among TKI-naïve patients (n = 160), the cORR was 88.8% and the IC-cORR was 76.5%; in TKI-pretreated patients (n = 113), the cORR was 55.8% and the IC-cORR was 65.6%. In TKI-naïve patients, the median DOR and median PFS were 44.2 and 45.6 months, respectively. In TKI-pretreated patients, the median DOR and median PFS were 16.6 and 9.7 months. The cORR in patients with G2032R mutation was 61.5% (8 of 13). Among 352 patients treated with taletrectinib 600 mg once daily, the most frequent treatment-emergent adverse events (TEAEs) were GI events (88%) and elevated AST (72%) and ALT (68%); most were grade 1. Neurologic TEAEs were infrequent (dizziness, 21%; dysgeusia, 15%) and mostly grade 1. TEAEs leading to discontinuations (6.5%) were low. Conclusion Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients. 2025-07-08T07:36:39Z 2025-07-08T07:36:39Z 2025-06-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, et al. Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun 1;43(16):1920–9. 0732-183X http://hdl.handle.net/11351/13367 10.1200/JCO-25-00275 40179330 001496344700009 http://hdl.handle.net/11351/13367 eng Journal of Clinical Oncology;43(16) https://doi.org/10.1200/JCO-25-00275 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf American Society of Clinical Oncology Scientia